← Back to all trials
Enrolling By Invitation
NCT07921823
An Observational Post-Authorization Safety and Effectiveness Study of Ravulizumab in Adult Patients Aged 18 and Older Diagnosed With Paroxysmal Nocturnal Hemoglobinuria Using Multicenter Electronic Medical Records in South Korea
Conditions: Hemoglobinuria, Paroxysmal
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Enrollment: 78
Sponsor: Yonsei University
Location: Yonsei University College of Medicine Seoul
Summary
This multicenter, retrospective observational cohort study aims to evaluate the long-term real-world effectiveness and safety of ravulizumab in adult patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) in South Korea over a 4-year post-marketing period. By analyzing electronic medical records (EMR) from participating institutions, the study investigates intravascular hemolysis control, transfusion avoidance, breakthrough hemolysis (BTH) characteristics, and overall clinical outcomes in an Asian population.
Eligibility Criteria
Inclusion Criteria:
1. Adult patients (18 years of age or older) with a confirmed diagnosis of Paroxysmal Nocturnal Hemoglobinuria (PNH) documented by flow cytometry.
2. Patients who initiated ravulizumab treatment on or before February 28, 2025, and have at least 6 months of follow-up data available.
3. To reflect real-world clinical practice, meningococcal (Neisseria meningitidis) vaccination status will be collected if available, but is not a mandatory requirement for study inclusion.
Exclusion Criteria:
1. Less than 18 years of age at the time of ravulizumab treatment initiation.
2. Known hypersensitivity to ravulizumab or any of its excipients.
3. Untreated Neisseria meningitidis infection at the time of ravulizumab treatment initiation.
4. Prior or concomitant use of other complement inhibitors for PNH (with the exception of prior eculizumab use).
Source: ClinicalTrials.gov (NCT07921823). StuddyBuddy aggregates publicly available trial information.